scholarly journals Optimizing Pharmacy Learner Rotations to Improve Clinical Productivity: A Study to Assess 3 Pharmacy Layered Learning Practice Models in an Inpatient Tertiary Care Oncology Unit

2021 ◽  
Vol 74 (3) ◽  
Author(s):  
Lauren (Ellie) Salsbury ◽  
Stephanie Lovering ◽  
Tiffany Nguyen ◽  
Jason Yung ◽  
Jason Wentzell
Keyword(s):  
Tertiary Care ◽  
Practice Models ◽  
Layered Learning ◽  
Oncology Unit

scholarly journals Maintaining an Adult Hematology/Oncology Service at a Tertiary Care Center during the SARS-CoV-2 Pandemic: An Eight-Week-Experience with a Newly Implemented Procedural Plan

2021 ◽  
pp. 1-6
Author(s):  
Philipp G. Hemmati ◽  
Dorothea Fischer ◽  
Frank Breywisch ◽  
Sabine Wohlfarth ◽  
Matthias Kramer ◽  
...  
Keyword(s):  
Clinical Symptoms ◽  
Care Center ◽  
Tertiary Care ◽  
Cancer Center ◽  
Staff Members ◽  
Oncology Service ◽  
Containment Measures ◽  
Vulnerable Patient ◽  
Set Up ◽  
Oncology Unit

Treatment of cancer patients has become challenging when large parts of hospital services need to be shut down as a consequence of a local COVID-19 outbreak that requires rapid containment measures, in conjunction with the shifting of priorities to vital services. Reports providing conceptual frameworks and first experiences on how to maintain a clinical hematology/oncology service during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic are scarce. Here, we report our first 8 weeks of experience after implementing a procedural plan at a hematology/oncology unit with its associated cancer center at a large academic teaching hospital in Germany. By strictly separating team workflows and implementing vigorous testing for SARS-CoV-2 infections for all patients and staff members irrespective of clinical symptoms, we were successful in maintaining a comprehensive hematology/oncology service to allow for the continuation of treatment for our patients. Notably, this was achieved without introducing or further transmitting SARS-CoV-2 infections within the unit and the entire center. Although challenging, our approach appears safe and feasible and may help others to set up or optimize their procedures for cancer treatment or for other exceedingly vulnerable patient cohorts.

scholarly journals Outbreak of Prototheca wickerhamii algaemia and sepsis in a tertiary care chemotherapy oncology unit

2018 ◽  
Vol 74 (4) ◽  
pp. 358-364 ◽  
Author(s):  
I.D. Khan ◽  
A.K. Sahni ◽  
Sourav Sen ◽  
R.M. Gupta ◽  
Atoshi Basu
Keyword(s):  
Tertiary Care ◽  
Prototheca Wickerhamii ◽  
Oncology Unit

scholarly journals Recommending form of anticancer drugs in oncology unit of a tertiary care teaching hospital

2021 ◽  
Vol 12 (2) ◽  
pp. 1201-1207
Author(s):  
Pandiamunian Jayabal ◽  
Nithiya Dhanasekaran ◽  
Shanmugasundaram S
Keyword(s):  
Anticancer Drugs ◽  
Care Delivery ◽  
Demographic Data ◽  
Tertiary Care ◽  
Dose Intensity ◽  
World Health ◽  
Tertiary Care Centre ◽  
Cost Effective Treatment ◽  
The World ◽  
Oncology Unit

Cancer has become a chief ailment and danger to the global society. It is one of the foremost reasons for demise in the world. A survey by the World Health Organization (WHO) indicates that 8.2 million people died from cancer in 2012 and it may rise to 19 million by 2025. Drug interactions connected through anticancer drugs are a global concern and should not be ignored. Nausea, vomiting or some other mild response to extreme myelosuppression may vary from adverse drug reactions. Analysis of prescription trend is a possible method in ascertaining the position of drugs in culture and it has to be taken out at every hospital regularly. The research is developed to examine the prescription pattern of anticancer drugs in the clinical oncology unit of a tertiary care centre in India. The patient's demographic data, medication name, type, dose, intensity and duration etc., have been analyzed in each prescription  Commonly utilized anticancer narcotics and different forms of cancer were identified and the national essential drug list percentage of the medicines used was analysed. The current study intended to assess the tendencies and pattern of prescribing anticancer drugs. The prescribing practises were apposite and were in agreement with WHO strategies. The present study seemed to sustenance best proposing performs in order to endorse cost effective treatment and improved health care delivery.

scholarly journals EMERALD: Emergency visit audit of patients treated under medical oncology in a tertiary cancer center: Logical steps to decrease the burden

2017 ◽  
Vol 06 (04) ◽  
pp. 186-189 ◽  
Author(s):  
Amit Joshi ◽  
Vijay M. Patil ◽  
Vanita Noronha ◽  
Anant Ramaswamy ◽  
Sudeep Gupta ◽  
...  
Keyword(s):  
Medical Records ◽  
Emergency Services ◽  
Medical Oncology ◽  
Tertiary Care ◽  
Cancer Center ◽  
Emergency Visits ◽  
Oncology Unit ◽  
Curative Intention ◽  
Tertiary Cancer Center

Abstract Background: We are a tertiary care cancer center and have approximately 1000–1500 emergency visits by cancer patients undergoing treatment under the adult medical oncology unit each month. However, due to the lack of a systematic audit, we are unable to plan steps toward the improvement in quality of emergency services, and hence the audit was planned. Methods: All emergency visits under the adult medical oncology department in the month of July 2015 were audited. The cause of visit, the demographic details, cancer details, and chemotherapy status were obtained from the electronic medical records. The emergency visits were classified as avoidable or unavoidable. Descriptive statistics were performed. Reasons for avoidable emergency visits were sought. Results: Out of 1199 visits, 1168 visits were classifiable. Six hundred and ninety-six visits were classified as unavoidable (59.6%, 95% CI: 56.7–62.4), 386 visits were classified as probably avoidable visit (33.0%, 95% CI: 30.4–35.8) whereas the remaining 86 (7.4%, 95% CI: 6.0–9.01) were classified as absolutely avoidable. Two hundred and ninety-seven visits happened on weekends (25.6%) and 138 visits converted into an inpatient admission (11.9%). The factors associated with avoidable visits were curative intention of treatment (odds ratio - 2.49), discontinued chemotherapy status (risk ratio [RR] - 8.28), and private category file status (RR – 1.89). Conclusion: A proportion of visits to emergency services can be curtailed. Approximately one-fourth of patients are seen on weekends, and only about one-tenth of patients get admitted.

Dihydro pyrimidine dehydrogenase deficiency in patients treated with capecitabine-based regimens: A retrospective tertiary care centre experience.

2016 ◽  
Vol 34 (4_suppl) ◽  
pp. 712-712
Author(s):  
Arvind Sahu ◽  
Vikas S. Ostwal ◽  
Anant Ramaswamy
Keyword(s):  
Dose Reduction ◽  
Dose Range ◽  
Dihydropyrimidine Dehydrogenase ◽  
Tertiary Care ◽  
Tertiary Care Centre ◽  
Exon 2 ◽  
Hand Foot Syndrome ◽  
Life Threatening ◽  
Grade 3 ◽  
Oncology Unit

712 Background: Capecitabine is an integral part of treatment of gastrointestinal cancers. Dihydropyrimidine dehydrogenase (DPD) enzyme is rate limiting in the metabolism of capecitabine, deficiency of which leads to myelsuppression, mucositis, diarrhea, hand foot syndrome (HFS) and rarely, death. Data regarding the toxicity of capecitabine in patients with DPD deficiency in the Indian context is scarce. Methods: 506 patients were treated with capecitabine containing regimens with a dose range of 1250 mg/m2/day to 2000 mg/m2/day during the period from June 2013 to May 2015 in the Gastrointestinal Medical Oncology Unit of our institution. Patients with Grade 3/4 toxicities requiring in-patient care (life threatening complications) were planned for DPD activity testing by Peripheral Blood PCR sequencing. Results: 27 patients developed Gr 3/4 toxicities during cycle 1 of capecitabine. It included mucositis in 22 (81.5 %), diarrhea in 25 (92.6%), HFS in 10 (37%) and myelosuppression in 4 (14.8%). 19 were found to be DPD deficient with 5 patients negative for DPD mutation. 3 patients did not do the DPD analysis as advised. Homozygous mutations were seen in 9 (33.3%) and heterozygous mutations in 10 (27%) of patients. More than one mutation was seen in 10 patients (37%). The relative frequencies of mutation were Exon 14 (44.4%), Exon 2 (25.9%), Exon 13 (25.9%), Exon 6 (11.1%) and Exon 18 (7.4 %). Post Cycle 1 of capecitabine, the drug was stopped in 5 patients (18.5%), regimen changed in 2 (7.4%) and dose reduction by 50% of the drug was done in the remaining patients. Despite dose reduction and change in therapy during Cycle 2, patients still had Grade 3/4 toxicities including mucositis in 7(25.9%), diarrhoea in 10 (37%), HFS in 7 (25.9 %) and myelosuppression in 6 (22%) of patients. Conclusions: Capecitabine can also lead to severe toxicities in DPD-deficient patients. Dose reduction of capecitabine in DPD deficient patients may not completely ameliorate the future risk of life – threatening complications. Screening for DPD deficiency prior to administration of capecitabine in toxicity prone nutritionally deficient Indian patients should be further evaluated based on this data.

Sign in / Sign up

Export Citation Format

Share Document